Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
October 22, 2024
Earnings Call Speaker Segments
James Bushnell
executiveGood day, and thanks for being with us. We put out a press release earlier today with full details about how we performed in the third quarter of 2024. You can find that release on our site, www.pmi.com. For definitions — including what we mean by smoke-free products — plus adjustments, other calculations, and reconciliations of the non-GAAP financial measures mentioned in this presentation to the closest comparable U.S. GAAP measures, please see Exhibit 99.2 in the company's Form 8-K filed with today's date, and also our Investor Relations website. Statements made today include forward-looking statements and projections about future results. Please look at the Forward-Looking and Cautionary Statements disclosure in today's presentation and press release, which reviews the various factors that might cause actual results to differ materially from projections or forward-looking statements. It's now my pleasure to introduce Emmanuel Babeau, our Chief Financial Officer. Over to you, Emmanuel.
Emmanuel Babeau
executiveThanks, James, and hello everybody. After a great first half, we turned in yet another remarkable Q3. Every core part of the business came in at or above what we had expected, fueling robust double-digit organic growth on both the top and bottom lines, margin improvement, and a notable step-up in adjusted diluted EPS growth measured in dollars. As we anticipated, IQOS and ZYN both picked up pace quarter over quarter. IQOS posted a major lift in HTU adjusted IMS volumes during Q3, a period that historically takes a hit from seasonality. That speaks to the powerful underlying momentum in the business, with adjusted IMS roughly 15% higher than a year earlier, helped by yet another very strong showing in Japan, renewed momentum in Europe, and encouraging results across a number of global markets. On ZYN, we kept working to expand U.S. production capacity to meet robust demand, which allowed share performance to stabilize and then improve sequentially through the quarter. That produced a major rise in sequential U.S. volumes, with growth exceeding 40% versus a year ago even with capacity limits. Beyond the U.S., nicotine pouch can volumes climbed by nearly 70%. Our combustibles unit likewise sped up to high single-digit growth in net revenue and gross profit, powered by continued very strong pricing, steady volumes and the gains from our cost actions. Our Q3 results overall capture how sound our strategy is, with underlying momentum spanning categories through solid volumes, pricing and smoke-free mix, all backed by cost efficiency measures. With adjusted operating income and diluted EPS both growing at a double-digit rate in currency-neutral and dollar terms, we are lifting our full-year guidance. Now to the headline financials for Q3; we achieved excellent organic revenue growth of 11.6%, powered by shipment volume growth of 2.9%, favorable smoke-free category mix and pricing. Pairing this positive top-line result with the extra favorable smoke-free mix benefit on profits and continued cost efficiencies let us reach growth of 13.8% in organic operating income and 18.0% in currency-neutral adjusted diluted EPS. That leaves out an unfavorable currency impact of $0.06, mainly from weakness in the Egyptian Pound, Argentine Peso and the strong Swiss Franc, partially offset by the Japanese Yen. Even with that currency headwind, our proactive pricing moves and accelerated cost initiatives generated 11.2% dollar growth in adjusted operating income and 14.4% dollar growth in adjusted diluted EPS, reaching a record $1.91. This earnings delivery, better than expected, mirrors IQOS and ZYN shipment volumes landing at the upper end of our expectations along with a very strong combustibles performance; on top of that we gained from a lower net financing cost, including higher interest income plus mark-to-market gains on derivatives we use to manage the currency profile of our debt, driven by interest rate volatility. Along with an excellent H1, this produces an impressive 17.2% year-to-date currency-neutral growth in adjusted diluted EPS, with double-digit organic top-line growth and 190 basis points of organic opening income margin expansion. When you factor in currency effects, our adjusted EPS came in at nearly 8% higher, and that shows how committed we remain to posting solid results measured in dollars. Now let's look at how each category performed financially in Q3, where both halves of our operation turned in outstanding numbers. Organically, smoke-free net revenues climbed 16.8% while gross profit rose 20.2%, which pushed gross margin up by 200 basis points. That mirrors a powerful quarter for IQOS, helped by manufacturing efficiencies, plus ZYN's ongoing accretion and a modest yet expanding input from VEEV. During Q3, smoke-free gross margins stood over 450 basis points above combustibles, and on a year-to-date basis they exceeded them by more than 200 basis points. On the combustible side, organic net revenue and gross profit growth sped up to nearly 9%. Organic combustible gross margins gained 10 basis points, and in dollar terms they gained 20 basis points — the second straight quarter of expansion after a difficult 2023. For the full year, we still aim for combustible gross margin expansion in both organic and dollar terms, since pricing and continuing cost programs more than counterbalance cost pressures, among them the EU single-use plastics directive. Turning to volumes now, we remain firmly on course for a fourth year in a row of volume growth. Across our business, total shipments rose roughly 3% in Q3 and also year-to-date — an impressive result — and every category and all four regions expanded during both periods. Adjusted IMS growth for HTUs in Q3 reached 14.8%, which captures the fundamental momentum behind IQOS, with Japan still performing strongly and Europe reaccelerating as we had anticipated. HTU shipments for Q3 totaled 35.3 billion units, landing at the high end of what we expected, while adjusted in-market sales growth outpaced shipments thanks to shipment phasing, which we flagged in H1. In our oral smoke-free segment, Q3 shipment volumes increased 22.2%, with ZYN fueling U.S. growth of 41.4% alongside exceptionally strong international results. Our VEEV e-vapor operation kept up its volume momentum during the quarter, hitting the equivalent of 1.2 billion units year-to-date. Cigarette shipments in Q3 rose 1.3%, ahead of the roughly 0.5% growth estimated for the overall international cigarette industry outside China and the U.S. This year's surprisingly sturdy industry performance stems from rising volumes in places where smoke-free products aren't allowed — Turkey, India and Brazil among them — combined with declining illicit volumes in several markets, driven in part by geopolitical developments. Turkey, India and Italy all made noteworthy contributions to our growth, which also shows solid category share results even with aggressive pricing. Our outstanding Q3 revenue figures came from the three structural pillars driving our top line: volumes, pricing, and the shift toward smoke-free. On top of our very strong volume growth, pricing added 7.5 points of growth. That came from powerful combustible pricing of 9.7%, IQOS HTU pricing of 3%, and a significant contribution from ZYN. Our smoke-free segment's favorable mix added 1.4 points, even with combustibles growing strongly, thanks to greater net revenue per unit for both IQOS and ZYN. Geographic mix, as in earlier quarters, remained a drag, though less so, since growth accelerated in Europe and the U.S. Looking at year-to-date net revenue drivers, they were quite comparable, with double-digit organic top-line growth resting on positive volumes, smoke-free category mix above plus 2 points, and robust pricing. Now on to operating income: we achieved notable Q3 organic margin expansion of plus 90 basis points, and plus 110 basis points in dollar terms. Organic gross margins rose 80 basis points, and plus 70 basis points in dollar terms. Once more, this stemmed from our higher margin smoke-free business, pricing, and continuous productivity savings throughout the value chain. Shifting to SG&A: even with a planned step-up in commercial activity, our organic cost evolution was basically aligned with top-line growth, delivering plus 40 basis points of margin expansion in adjusted dollar terms, backed by cost efficiency actions. As we said before, we aim for an organic rise in SG&A below the rate of net revenue growth this year, while continuing to support our smoke-free expansion through sustained commercial investment.
Emmanuel Babeau
executiveDuring the third quarter, we achieved an additional $180 million in gross cost efficiencies, bringing us to nearly $490 million for the year so far, with efforts particularly targeting manufacturing and back-office expenses. Though this is just the initial year, we're making solid headway on our 2024 to 2026 goal of $2 billion in gross savings. Looking at the year-to-date figures, our adjusted operating income margin trend has been quite favorable too, showing organic growth of plus 190 basis points and a dollar-based increase of plus 40 basis points; we're on track to achieve our full-year target of growth in both measures. Now shifting to our IQOS segment, which is marking a decade since its debut launches in Japan and Italy. IQOS stands as the top smoke-free product globally, bringing in more than $10 billion in yearly net revenues. Even with the remarkable expansion and triumph of the brand during that period, there's a significant opportunity for further growth in the years ahead as additional members of the world's one billion legal-age smokers adopt improved options. In fact, strong expansion persists this year. Last quarter, we discussed anticipating a robust second-half performance, with ongoing user acquisition driven by our commercial initiatives, such as events marking the 10-year anniversary. As anticipated, third-quarter momentum picked up, showing a 14.8% year-over-year rise in HTU adjusted IMS and a notable sequential increase of 1.8 billion units from the second quarter, which is particularly striking given that this period usually faces seasonal headwinds. This indicates a resurgence of double-digit growth in Europe, ongoing strong performance in Japan, and even greater acceleration in our global markets. We anticipate continued robust expansion in the fourth quarter. IQOS's achievements stem from technology, commercial expertise, brand development, and innovation in both devices and consumables. After the effective introduction of the IQOS ILUMA i device in Japan earlier in the year, we're broadening its availability to additional countries, such as Italy, Greece, Portugal, Romania, and Switzerland. Now concentrating on IQOS in Europe, I'm happy to share that third-quarter adjusted IMS growth rebounded to plus 11.3% after a slower second quarter. This encompasses renewed growth in areas undergoing the transition phase from the characterizing flavor prohibition. Most EU HTU volume is now subject to the ban, and we're seeing a comeback to strong growth in places like Greece, Romania, and Portugal. After the larger-than-anticipated initial effect in the second quarter, we're glad to note positive volume trends in Italy. This stemmed from the introduction of newer HTU versions, such as our mainstream-priced DELIA and tobacco-free LEVIA, which together made up nearly 7% of Italy's HTU offtake within three months of release. Additionally, we're witnessing great momentum in countries like Germany, Spain, and the UK, along with increasingly steady growth across all markets, irrespective of IQOS penetration. The regional third-quarter adjusted HTU share climbed by +0.8 points year-over-year to 9.5%, and slightly decreased from the previous quarter because of the usual effect of higher combustible volumes during summer. On a four-quarter moving average basis, adjusted IMS volumes for HTU came in at 13.2 billion units, which kept us at a high share within the category alongside solid growth quarter over quarter. When we look at offtake share in our major European cities, rapid advancement continues across a great many of them. More and more of these cities are recording gains above 2.0 points versus a year earlier, and that comparison is the most telling one once you account for seasonality. A few worth naming specifically are Budapest, Athens, Bratislava, Bucharest, London and Amsterdam. Now shifting to Japan, we posted a fourth straight quarter — the eighth in a row — of double-digit improvement, with adjusted HTU IMS rising 14% to hit 10.9 billion units on a four-quarter moving average. Meaningful results keep coming from our commercial programs, as innovation across devices and consumables drove a market share gain of 3.2 points, bringing us to 29.8% in Q3 and pushing past the 30% landmark during September; the IQOS ILUMA i device, launched in Q1 and delivering better consumer satisfaction, is part of that impact. As the prior slide showed, IQOS HTU offtake shares in key cities like Tokyo keep climbing quickly. We noted before that Tokyo's offtake share for the whole heat-not-burn category hit 50% earlier in the year. That's now the case in eight cities in total, among them Yokohama, Kawasaki, Sendai and Fukuoka, while a number of others are closing in fast on that same threshold. It's a clear signal of the lasting growth runway in a market where penetration is already elevated. Zooming out globally, we keep seeing quite strong growth in many markets worldwide, as key city offtake shares make clear. Among these are cities in Saudi Arabia, Mexico and Egypt, with Cairo getting close to a 10% share. In Jakarta, offtake share above 5% signals the strong pickup in Indonesia, where we're pressing ahead with geographic and portfolio expansion, among other things through a widening range of clove TEREA HTU variants. Last, I want to mention duty-free, where the continuing travel rebound plus the strength of our multicategory portfolio produced dynamic growth, with ZYN and VEEV increasingly available next to IQOS. Switching to ZYN now: the top U.S. smoke-free brand keeps showing very strong underlying momentum. As we said before, we're working to raise production volumes step by step, and that showed up in a sequential acceleration to 149 million cans shipped during Q3. While we kept working through those supply constraints, ZYN's category share leveled off and then returned to sequential growth over the course of the quarter, even after a further list price increase of $0.15 per can took effect at the beginning of September. We still expect shipments to align with consumer demand at some point in the fourth quarter. Judging underlying demand isn't an exact science given the current circumstances, but our promotional and commercial activity has understandably been reduced, since we're prioritizing existing consumer needs rather than growing the legal-age user base from other nicotine categories. With continuing efforts to increase our U.S. With production capacity reaching approximately 900 million cans during the whole of 2025, plus substantial growth after 2025 coming from the new Colorado plant we have planned, we feel our position is strong for seizing ZYN's opportunity in the years ahead. Driving sector standards in under-21 prevention stays a commitment of ours, through policies and initiatives meant to stop youth access. Social media influencers are banned under our rigorous U.S. marketing code, and we turn down any requests for partnerships of that kind. Age verification technology is deployed across all the product websites we own, and we work with WeCard and TruAge to back age restriction checks when sales happen at retail. On the whole, the outcome of our work encourages us, and I will return to that point. Fighting the trade in illicit tobacco and nicotine products stays a leading priority, and we put a meaningful amount of resources behind those efforts. Strong governance and supply chain controls are established on our side, and where needed we take suitable action, such as restricting and/or ending sales to particular customers across both the online and traditional trade, and these control measures keep getting better; in addition, we watch imports closely for products that might be illicit or that infringe our patents, and we are dedicated to acting independently or together with the authorities to stop such products from being illegally commercialized.
Emmanuel Babeau
executiveOur multicategory strategy keeps building steam, since we draw on the power of our top brands while extending the footprint of our smoke-free lineup. When it comes to nicotine pouches, our aim is to responsibly develop this category through ZYN in markets outside the U.S. Rising awareness of the category and greater interest from legal-age nicotine consumers are producing encouraging momentum across a widening set of geographies. Year-on-year, we have broadened ZYN's availability to 30 markets, among them the Philippines, Mexico, a number of European countries, and duty-free channels. Even though distribution remains limited in certain markets, we keep seeing robust momentum in Mexico, Pakistan, South Africa, the UK and duty-free. Scandinavia also continues to see this category expand at a strong pace. E-vapor results stayed dynamic during Q3, and in September we achieved profitability at the product contribution level, supported by outstanding volume momentum and improvements in cost of goods sold. Europe leads the way, with closed pods steadily capturing share from disposables, and we hold the category lead thanks to our flagship VEEV ONE closed-pod system in multiple markets, such as Italy, Romania and the Czech Republic; repeat purchasing and regular use look healthy in a competitive setting, while we keep expanding distribution and brand awareness. Beyond Europe, we are putting investment behind VEEV to secure future profitability in several focus markets; the initial phase of our IQOS 3 consumer pilots in the U.S. is now underway, marked by the launch of our "Be the first" campaign in Austin, Texas. As we have said before, the emphasis is on engaging adult consumers and fostering awareness via category and brand education within legal-age smoker communities. We expect no commercial volumes during 2024. What we learn from these pilots in Austin and other cities will help us refine our approach ahead of the at-scale launch of IQOS ILUMA, for which we still assume an FDA authorization in H2, 2025. Last, a quick note on our Wellness & Healthcare business. As we shared in September, we have signed an agreement to divest Vectura Group and anticipate the deal will close by year-end. Holding Vectura mattered to us in building the skill and scientific know-how needed to move our inhaled therapeutics pipeline forward. Considerable progress has occurred on that front, yet because Vectura's scientific engagement and commercial CDMO relationships were suffering from unjustified resistance to PMI's ownership, we feel Vectura's future overall is best served with a new owner. Alongside the divestment, we announced master service agreements to underpin continued development of our proprietary inhaled therapeutics pipeline. Our Wellness & Healthcare strategy remains in place, and we look forward to bringing you updates on future developments, among them launches of consumer wellness products. Turning now to combustibles, where our portfolio turned in a very strong financial performance. Net revenues rose +8.6%, powered by Q3 pricing of +9.7%. That figure reflects pricing implemented during the quarter as we stay focused on maximizing value, and it was spearheaded by markets including Egypt, Turkey and Germany. Like I mentioned before, this generated a strong +8.7% lift in gross profit. Given pricing that came in above expectations at +8.8% year-to-date, our full-year pricing outlook is now +8 to +9%. Cigarette volumes held up well, since worldwide industry dynamics continue to be favorable. As I noted previously, much of this comes from markets where smoke-free products are banned or still at an early stage, along with the effects of major industry initiatives and geopolitical developments on global illicit trade across several markets. In Q3 and year-to-date, our cigarette category share rose by +0.1 points. Marlboro and our global brands overall both posted their best quarterly share since the 2008 spin-off, which also lifted value share positively. Last week we announced that at long last there has been some movement toward settling the cigarette-related litigation claims in Canada that have stretched on for decades. RBH, our Canadian affiliate, was deconsolidated back in 2019 once it entered the mediated CCAA process. Under the mediator's proposed plan, the industry would settle for approximately $23.5 billion, funded by cash and cash equivalents in Canada plus future combustible profits there. Whether RBH's financial results get reconsolidated once the plan takes effect would depend on the final terms of the Proposed Plan and U.S. GAAP. Our estimate is that reconsolidation would add to PMI's cash and cash equivalent, cash flow and adjusted EBITDA, adjusted operating income, and adjusted EPS figures. For more detail, please see last week's press release. Turning to sustainability now. We continue to make solid progress on our product transformation targets, including access to smoke-free products. Those products have reached 92 markets, keeping us on track toward our aspiration of 100 by 2025. Keep in mind, a significant number of markets still lack smoke-free products because of regulatory constraints — for heated tobacco, that's nearly one fifth of industry volumes excluding China, as we discussed at our Investor Day last year; we're also progressing well on our goal for low and middle-income countries to account for over 50% of smoke-free products markets. Expanding access to smoke-free products is aimed specifically at legal-age nicotine users, and combating underage nicotine use remains a crucial priority; we take encouragement from the U.S. 2024 National Youth Tobacco Survey, which found youth usage of nicotine pouches still very low at under 2%, with no statistically significant change year-on-year even as the overall category grew strongly. Results like these are only possible with responsible stewardship of the category, and we remain committed to advancing standards in youth access prevention via a multi-stakeholder approach. Another key pillar of our sustainability strategy is tackling our company's environmental impacts. We're pursuing carbon neutrality in our direct operations, including certifying every one of our manufacturing facilities as carbon neutral. Year-to-date, we certified four more sites, which brings us to 52% in total. For the rest of our footprint, we have specific initiatives in place so we can reach that 100% goal by 2025. On top of that, we're moving forward with the Alliance for Water Stewardship standard, and we've certified another factory so far this year, which brings us to 86% versus our 100% target for 2025. By pairing the work we're already doing to tackle environmental impacts with strong, disciplined reporting practices, we think we're in good shape for the reporting requirements coming down the line, including the EU Corporate Sustainability Reporting Directive. All right. Now to the full-year outlook. Given this year-to-date performance that came in stronger than we expected, we're lifting our forecasts for the full year on volume, organic sales growth, organic OI growth, and the bottom line on both a currency-neutral and U.S. dollar basis. Starting with volumes, we're aiming for record organic growth and raising our outlook to +2% to +3% for total shipment progression. Inside that, we still anticipate adjusted IMS HTU volume growth of roughly +13% and shipment volumes of roughly 140 billion. This forecast still bakes in an impact of just over 2 billion units from the EU characterizing flavor ban, along with no volumes in Taiwan, where we're still waiting on regulatory approval. For U.S.
Emmanuel Babeau
executiveFor ZYN, we're projecting shipment volumes toward the higher end of what we previously guided, between 570 million and 580 million cans, which mirrors the headway we've made expanding capacity along with demand that remains strong. Our outlook additionally takes into account a solid combustibles showing, powered by a total category that has proven resilient, as we laid out before. Because of stronger volumes combined with faster pricing and a mix that keeps shifting toward smoke-free, we're lifting our projection for organic net revenue growth to roughly +9.5%; that figure incorporates robust double-digit organic gains in smoke-free net revenue and ought to bring the total for the year to nearly $15 billion; thanks to this better top-line result, together with IQOS and ZYN operating leverage plus additional cost efficiencies, we're now also boosting our forecast for adjusted organic OI growth to +14% to +14.5% for the year; we remain focused on achieving adjusted gross margin expansion for smoke-free products and combustibles alike, as well as adjusted OI margin expansion for total PMI, each measured both organically and in dollar terms. In line with that, we're raising our projection for currency-neutral adjusted diluted EPS growth to +14% to +15%, which likewise accounts for net financing costs coming in lower than expected, including greater interest income. That works out to a range of $6.45 to $6.51, which includes an unfavorable currency impact of $0.40 for the year at prevailing rates. The $0.06 rise in anticipated currency headwind mostly mirrors the same elements seen in Q3. Measured in U.S. dollars, this forecast amounts to very strong growth of roughly +7% to +8%. As this forecast shows, we anticipate yet another robust delivery in Q4, even with a tougher top-line comparison regarding how shipments are mixed across categories. We're also aiming for one more quarter of adjusted gross and operating margin expansion, which includes a deliberate step-up in commercial investments behind our smoke-free brands. Net financing costs in Q4 will probably be higher sequentially, particularly because of the mark-to-market benefit in Q3 stemming from interest rate market volatility that I referenced earlier. Our expectation of strong operating cash flow, roughly $11 billion for the year, hasn't changed, and after accounting for the latest currency movements, we now aim for a 0.3 times to 0.4 times improvement in our net debt to adjusted EBITDA ratio in 2024. That keeps us squarely on pace to reach our target ratio of about two times by the close of 2026, with buybacks to be weighed, pending Board approval, as soon as we approach that goal. To wrap up, we turned in yet another excellent quarter, one that mirrors the strong underlying momentum in our business alongside the proactive measures we've taken to back superior growth in dollar terms. We're hitting every key metric, with volume and pricing that lead the field, plus considerable margin expansion and earnings growth on both a reported and dollar basis. We're raising our growth outlook for a remarkable 2024, with growth rates that sit comfortably above our 2024 to 2026 targets. Although the industry dynamics weighing on combustible volumes could be particular to 2024, the main drivers behind our growth are structural and sustainable alike. Adults who smoke legally want alternatives without smoke, so we're creating robust, profitable premium labels — IQOS, ZYN, and VEEV — to steer the smoke-free segment. With our forceful smoke-free shift still underway, we see meaningful additional chances ahead, both across the U.S. and around the globe. Notably, in September we increased our dividend, marking a 17th consecutive year of doing so, consistent with our progressive approach. Our cash generation remains solid and keeps expanding, which supports reinvesting for long-term growth as well as giving us room for considerable returns to shareholders. Many thanks for listening, and at this point we're delighted to take your questions.
Bonnie Herzog
analystAlright, thanks. Hey Emmanuel, doing okay I hope?
Emmanuel Babeau
executiveMorning, Bonnie.
Bonnie Herzog
analystI want to ask about IQOS. Could you possibly elaborate a bit more on what shipment volumes for IQOS are expected to do, since growth in shipped units slowed to the high single digits during Q3, whereas previously it had been in the double digits? I realize timing effects and seasonality played a part. Still, perhaps you could give us a fuller update on that for the quarter, and on how it might swing back the other way in Q4. I'd also like additional detail on the volumes for IQOS in East Asia, where things have slowed down too — what's driving that, and do you anticipate shipments picking up in that region during Q4?
Emmanuel Babeau
executiveOf course, Bonnie, happy to, and this lets me return to the point that regarding IQOS, I strongly encourage you to focus on in-market sales, the adjusted in-market sales, since that's the finest proxy available to us for consumer off-take. On that measure, the encouraging development was that the reacceleration we had anticipated got confirmed, and we had been signaling that we expected IQOS momentum to speed up during H2. That is precisely what our Q3 adjusted in-market sales show, since we're nearly at 15%. You raised the topic of East Asia. In fact, Japan once again posted roughly 14% of adjusted in-market sales. So IQOS's market stays incredibly vibrant even though we already hold close to 30% share, yet we keep delivering strong double-digit figures, and that was quite welcome news. What drove the Q3 acceleration comes down to, as I mentioned, sustained very robust dynamism in Japan. Incidentally, South Korea is performing well too; and we — I believe we're presenting the figure for Seoul, where our market share is growing nicely; beyond that, Europe saw a reacceleration. And I'm aware we fielded plenty of questions about how confident one can be that Europe will reaccelerate. We understood we were moving through that transition period related to the flavor ban. Now we observe the market gradually emerging from the ban's disruption, with reacceleration occurring. Italy was, naturally, the country that reaccelerated during the third quarter, and it was gratifying to watch Italy plainly getting IQOS growth going again on a very strong footing. And we went back to double-digit growth on adjusted AMS in Europe during Q3. Then there are quite a few other markets globally. I'd say we're seeing momentum accumulate there, which bodes very well going forward. I could name, naturally, Indonesia, Saudi Arabia, Mexico, and I think the EU as well in this context. So, in a lot of markets we're seeing — Egypt being one, though Egypt has now had growth for over a year — we're seeing genuine momentum building behind IQOS, and of course we're only at the start there. So there's plenty of potential, but it's very encouraging because it means we have a good growth relay beyond Japan and the EU going forward; that's really what Q3 showed us. Then you raised the question about shipments. Well, we've been signaling that shipments would be — their path would be out of sync with consumer off-take. We saw some very strong growth during the first two quarters, driven notably by the year-on-year comparison. There was, of course, disruption in the Red Sea that created some shipments early in the year. And so, as things stand, our shipments for the third quarter are somewhat below adjusted IMS. And across the nine months, if you like, we're moving toward a situation where adjusted IMS and shipments gradually even out. That's what we're observing. And in Q4, we'll see more of that evening out, because two factors are coming into play. The first concerns the Red Sea disruption: we'll get some reversal in Q4, so that will weigh negatively on shipments; and we're also up against some tough comps from last year, since we were building inventory to get ready for the flavor ban in Europe; so that's a tough comp when it comes to shipments last year; but ultimately, you should expect adjusted IMS and shipments to move in parallel over a given period; and as we've said, we still expect, for Q4, renewed momentum in consumer off-take, or what we call adjusted market sales, which is really the thing that counts. That's what matters, because that's what speaks to the health of IQOS.
Bonnie Herzog
analystYes. Okay. That all tracks, and it genuinely helps. Thanks. Then perhaps a follow-up about ZYN; the supply issues seem to be loosening up, which is excellent; so I merely wanted to check with you, Emmanuel, whether you remain on schedule to bring supply fully back to normal during this quarter? Or could it possibly spill over into perhaps the start of next year? And once that occurs, how soon do you anticipate ZYN recovering a portion of the market share it lost? And I'm just wondering what part any potential increased promotions might play, I suppose, if they play one at all? What's your thinking there? Thank you.
Emmanuel Babeau
executiveSure. Regarding ZYN, Bonnie, we indicated at some point in Q4, we'll have the supply available to the market, satisfying consumer demand, which to make clear once more, doesn't mean we will have completely refilled every inventory level. At that stage, we believe, based on what we can gauge about consumer demand, that whatever we deliver to the trade will match whatever the consumer takes from the trade, purchases from the trade. But then there will surely be — and I can't say what will occur over the course of this quarter; but I believe we remain in that outlook still, though that's likely more a matter for 2025, there will be a refilling of the out-of-stock position; and we will step by step — but that will only occur step by step probably across 2025, return the inventory level to where it ought to be normally, and that surely will require several months while we keep raising the capacity. Recall, we stated that for the entire year 2025, we aim for total capacity of approximately 900 million can. Naturally, that's a capacity we will build up step by step; it won't exist at the year's start; and I would say the refilling and getting back to a completely normal state will only occur step by step across 2025; and naturally, once we can be more precise on that, we will be more precise regarding the topic. So that covers supply. As for recovering share, what we've observed is that, in reality, once ZYN's availability declined, we saw the category decelerate since, clearly, it appears a number of ZYN buyers have no intention of purchasing a different brand; and so, when they can't locate their ZYN, they might be making or using something else. But that likely has been slowing the category somewhat; we'll see how we recover step by step; we saw during the latter portion of Q3, some sequential gains in our market share, which is encouraging. We think we have a favorable outlook as we restore product availability, yet it's hard to be more precise than that at this point.
Analyst
analystOkay, thanks. I'll relay that.
Emmanuel Babeau
executiveThanks.
Gaurav Jain
analystHi. Good morning, Emmanuel.
Emmanuel Babeau
executiveGood morning, Gaurav.
Gaurav Jain
analystI’ve got a few questions for you. If we look at the international cigarette business, your pricing guidance was raised to 8% to 9%, and even so, volumes are coming in positive. The reasons you cite for such strong volumes — no SBD in Brazil and Turkey, and probably no smuggling out of Russia, Belarus, and those other countries — ought to keep applying in FY 2025. So wouldn’t FY 2025 also be quite a robust year for international cigarette volumes and pricing? And on that same point, could you also say whether any disruptive excise tax increases are coming in the next few months?
Emmanuel Babeau
executiveThanks, Gaurav, for the question. I’d rather not start commenting on 2025 right now; naturally, at the right time, we’ll give you our view of the year ahead. What we’re seeing in 2024, I think, is well identified: we’re talking about a set of markets where smoke-free products aren’t permitted. In some cases prevalence is rising, in others demographics are working in favor of cigarette consumption. India, for example, is a clear case when it comes to demographics. And how long all of that will last, and what the continuation of this trajectory will be, is hard to say. I'd say there's reason for some caution when it comes to the outlook, even though I certainly can't say that everything wraps up on December 31, 2024; the path for 2025 remains unclear to us. The encouraging part is definitely our ability to increase volume, expand our segment share, and at the same time push pricing upward quite aggressively — that reflects how strong our brand is — and the 9.7% figure in Q3 really was an impressive pricing gain. Please don't take that as a forecast for Q4, but Q3 was quite strong. What this shows is that our approach in this segment is succeeding and producing results — and I believe we've been upfront that our aim here is to get the most out of combustible products so we can support and enable the quickest possible shift toward smoke-free. Also, keep in mind that we stated 2025 should bring several favorable things for combustible cigarettes on the cost of goods side, with reduced pressure there. So prices will definitely keep going up going forward. That said, you shouldn't treat that 8% to 9% figure as what we're guiding to long term. We've consistently described ourselves as being in the mid-single-digit range over the medium term. Also, the drag from cost of goods ought to ease, and that likely helps combustible cigarette profitability. On excise tax, at this point I don’t have anything meaningful to share—just the usual sort of conversation—but it’s still fairly early. You know how it goes: a lot of the decisions get made in November, maybe even December, so things should come into sharper focus as we get to the end of the year. That said, so far I wouldn’t point to anything specific or unusual.
Gaurav Jain
analystAlright, thanks. My follow-up concerns what you said about e-cigarettes. You mentioned having shipped 1.2 billion sticks so far this year. If I've got it right, the conversion you're applying is that 10 sticks equal 1 ml. Assuming a single pod holds 0.7 ml, that works out to 160 million pods being shipped. On that basis, your e-cigarette revenue run rate would land somewhere between $300 million and $400 million, which is where your contribution basis breakeven sits. So is my rough estimate in the right area, and are all those figures settled?
Emmanuel Babeau
executiveYes, I can definitely verify that 1 ml is the same as 10 sticks, 10 cigarettes. That's the equivalence. As for ballpark, I won't give an exact confirmation, but on volumes you're not a million miles from the reality. Regarding revenue, I'll refrain from commenting.
Gaurav Jain
analystSure, thank you so much.
Emmanuel Babeau
executiveThank you.
Faham Baig
analystHello, Emmanuel. Hello, James. I appreciate you fielding my questions. I have two, if I may. First, I'd like to begin with vapor, especially since a competitor of yours pointed out that when it comes to fully switching smokers over, vapor is achieving more success in Europe compared to heated tobacco. I realize I've raised this point previously, but I was hoping to hear your most recent perspective on the matter, and also whether you're observing faster vapor uptake as you bring VEEV into a number of markets; and my second one concerns nicotine pouches in the U.S. In what you said ahead of time, I picked up that you've noticed certain illegal items entering the marketplace. A portion of those might be violating your patents. Might you elaborate a bit on the steps you're taking now or plan to take? And in what ways do you expect that to be distinct from the situation we currently observe with vapor in the U.S., if you would?
Emmanuel Babeau
executiveCertainly, Faham. Happy to. So regarding vaping being more effective at persuading smokers, that isn't what we observe at all. The reality is quite distinct. It's rather clear that compared with heat-not-burn, heating up a liquid that contains no tobacco produces an extremely, extremely different set of experiences. And I believe every market demonstrates that the shift from smokers toward heat-not-burn is plainly far, far larger and far superior to what happens with vaping. Plus the achievements of IQOS make that abundantly clear, I should mention, and I won't revisit how IQOS has performed. I don't believe we're genuinely witnessing any speeding up when it comes to vaping uptake. Today the vaping market, the vaping segment, is being affected by a great many regulatory changes or possible changes. We're aware that one issue within the vaping segment is having an irresponsible company pursuing elaborate flavors, engaging in marketing practices that are unacceptable, which can lead to consumption by minors and can cause certain disruptions. We're aware that the disposable segment in particular has been producing some of that; yet when you consider what can be stated about legal-age nicotine users, I don't think we can point to any meaningful acceleration coming from vaping. As for the nicotine portion in the U.S., and your inquiry about our actions, could you first permit me a broad remark? I believe PMI stands at the forefront, truly at the very forefront, regarding combating illicit trade. That holds for the U.S., and it holds across the entire globe; we dedicate enormous resources — meaning investments — toward combating illicit trade, collaborating with authorities and regulators in numerous nations to accomplish that; and to us, this is an extremely, extremely significant battle, an extremely significant fight; thus, the U.S. is no exception. And indeed, whenever we learn about illicit activity, whenever we learn about a product that potentially infringes our patent, we take action. I believe that during my remarks, I pointed to a few of the actions we undertake. Once we pinpointed the sources that might be located beyond the U.S., we had the option of going as far as cutting off sales to those sources entirely. I've said it. We're collaborating with distributors; that can involve informing them, raising awareness about illicit product being written to a distributor. It can mean dispatching a cease and desist letter to a distributor or retailer where we spot a problem. And we handle that by ourselves or alongside the regulator, as I mentioned, in the U.S. just like anywhere across the globe. So rest assured, we treat this with the utmost seriousness.
Faham Baig
analystThanks, Emmanuel.
Emmanuel Babeau
executiveThank you very much.
Priya Ohri-Gupta
analystHello, Emmanuel — I really appreciate you taking the time to meet with me.
Emmanuel Babeau
executiveHey there, good to talk.
Priya Ohri-Gupta
analystI've got just a couple of quick items for you. To start, it seems you lowered the upper bound of your expected deleveraging for this year slightly — could you speak to what was behind that? Then, second, you've got a rather large sum of maturities coming due across 2025. Given where the markets are and the opportunity they present, any views on moving part of that refinancing up into what's left of this year? Thanks.
Emmanuel Babeau
executiveYes, happy to take both of those. Regarding the guidance for deleveraging being narrowed just slightly and very modestly, the reason is the euro's strength at the close of September — since, as you're aware, a meaningful portion of our debt is denominated in euro, so when the euro rises against the dollar, that can create a sort of one-time effect, because we always face this mismatch: EBIT gets calculated using an average rate for the year, while the debt gets calculated at the spot rate on December 31. So we'll see where we end up. Still, the direction is unmistakable. And you might have noticed that by the close of the third quarter, we had produced $8.2 billion in cash flow, which is simply $2.3 billion more than the cash flow we generated at the close of Q3 2023. So we're generating a great deal of cash, naturally helped by very strong business momentum, and that's a positive. Yes, I mean, I certainly won't rule out the chance for us to act in the refinancing market over the next few months. I won't go into detail on that right now, and we have several options available. But rest assured, we're already at work on how to arrange the best refinancing once again in the months ahead for PMI.
Priya Ohri-Gupta
analystThank you so much.
Emmanuel Babeau
executiveThank you.
Gaurav Jain
analystHey folks, I wanted to ask something else regarding that settlement of the Canadian litigation. Are those payments going to be deductible for tax purposes? Also, in this lengthy COVID-related matter, when do you expect a final resolution to occur?
Emmanuel Babeau
executiveGaurav, thanks. Regarding the Canada litigation, at this point you have whatever we are able to state in the press release we put out last week; that is too early to draw conclusions. And like I mentioned, whether it will be tax-deductible is something I cannot tell you. Naturally, we will inform you the moment we find out. However, right now, I cannot provide an answer. And as you might have noticed in our release, where we disclosed everything we could at this point, the proposed solution that the mediators have placed on the table still contains quite a few elements that need to be finalized. And naturally, when the final terms are available, we will return to you with that answer, naturally, and also address every question regarding what the impact on PMI would be from a final settlement.
Gaurav Jain
analystThank you so much.
Emmanuel Babeau
executiveThank you.
James Bushnell
executiveWe appreciate you being with us on this call. Should anything else come up afterward, feel free to get in touch with the Investor Relations team. I hope the remainder of your week goes well, along with the rest of earnings season.
Emmanuel Babeau
executiveLook forward to speaking to you soon. Thank you. Have a great day.
Operator
operatorThis concludes today’s conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.